Northern Trust Corp Increases Stock Holdings in Compugen Ltd. (NASDAQ:CGEN)

Northern Trust Corp raised its position in Compugen Ltd. (NASDAQ:CGEN - Free Report) by 936.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 941,825 shares of the biotechnology company's stock after buying an additional 850,997 shares during the quarter. Northern Trust Corp owned approximately 1.06% of Compugen worth $1,441,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CGEN. Commonwealth Equity Services LLC acquired a new position in shares of Compugen in the fourth quarter valued at approximately $32,000. Oppenheimer & Co. Inc. increased its holdings in shares of Compugen by 187.3% in the fourth quarter. Oppenheimer & Co. Inc. now owns 55,602 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 36,252 shares during the period. Marshall Wace LLP grew its holdings in Compugen by 84.9% during the fourth quarter. Marshall Wace LLP now owns 88,169 shares of the biotechnology company's stock worth $135,000 after acquiring an additional 40,494 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Compugen by 15.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 317,500 shares of the biotechnology company's stock worth $486,000 after acquiring an additional 43,165 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Compugen during the fourth quarter worth $103,000. Hedge funds and other institutional investors own 12.22% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen lowered Compugen from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Compugen Stock Down 2.6%

CGEN stock traded down $0.04 on Friday, reaching $1.49. 77,662 shares of the company's stock were exchanged, compared to its average volume of 366,377. The stock has a fifty day moving average of $1.39 and a 200-day moving average of $1.67. Compugen Ltd. has a twelve month low of $1.13 and a twelve month high of $2.66. The firm has a market cap of $132.96 million, a PE ratio of 74.50 and a beta of 2.61.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings data on Monday, May 19th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.02). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The business had revenue of $2.28 million for the quarter, compared to analyst estimates of $3.70 million. During the same period in the prior year, the company earned ($0.08) EPS. On average, equities research analysts predict that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.